Drug intelligence / Profile preview

Saralasin

Development stage: Discontinued
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

Saralasin is a synthetic octapeptide analog of angiotensin II, in which the amino acids at positions 1 and 8 are replaced by sarcosine and alanine, respectively. It acts as a competitive antagonist at the angiotensin II receptor with partial agonist activity. The drug was primarily used as a diagnostic agent to distinguish renovascular hypertension from essential hypertension but was discontinued due to issues with diagnostic accuracy. Mechanistically, saralasin blocks the effects of endogenous angiotensin II on vascular smooth muscle (Angiotensin II receptor type 1) and also exhibits agonist activity at the Angiotensin II receptor type 2. It is administered intravenously.

Other names: SaralasinumSaralasineSaralasina34273-10-4

Targets

AGTR2 (AT2)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on Saralasin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saralasin.

Explore the full profile